Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing

Neoplasia (United States)

Volumn 15, Issue 11, 2013, Pages 1231-1240

  Pflueger, Dorothee ^a,b,c   Sboner, Andrea ^d   Storz, Martina ^a   Roth, Jasmine ^a   Compérat, Eva ^e   Bruder, Elisabeth ^f   Rubin, Mark A ^d   Schraml, Peter ^a   Moch, Holger ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Molecular Biomedicine   (Switzerland)

^c Competence Center for Systems Physiology and Metabolic Diseases ^*  (Switzerland)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CONTACTIN 3; ELONGATION FACTOR 1; ELONGATION FACTOR 2; INTERLEUKIN 18; MUCIN 1; POLYCYSTIN 1; TRANSCRIPTION FACTOR TFE3; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SCHOOL CHILD; SOMATIC MUTATION; TISSUE MICROARRAY; VALIDATION PROCESS;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CHILD; CONTACTINS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PEPTIDE ELONGATION FACTOR 1; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, RNA; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VESICULAR TRANSPORT PROTEINS; YOUNG ADULT;

EID: 84888426188     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131544     Document Type: Article

References (45)

1. Ross H and Argani P (2010). Xp11 translocation renal cell carcinoma. Pathology 42, 369-373.
2. Folpe AL and Deyrup AT (2006). Alveolar soft-part sarcoma: a review and update. J Clin Pathol 59, 1127-1132.
3. Argani P, Aulmann S, Illei PB, Netto GJ, Ro J, Cho HY, Dogan S, Ladanyi M, Martignoni G, Goldblum JR, et al. (2010). A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol 34, 1395-1406.
4. Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, Chen HW, Pathan N, Krausz T, Dickson BC, et al. (2013). Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer 52, 775-784.
5. Kim SH, Choi Y, Jeong HY, Lee K, Chae JY, and Moon KC (2011). Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma. Virchows Arch 459, 299-306.
6. Macher-Goeppinger S, Roth W, Wagener N, Hohenfellner M, Penzel R, Haferkamp A, Schirmacher P, and Aulmann S (2012). Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol 25, 308-315.
7. Malouf GG, Monzon FA, Couturier J, Molinié V, Escudier B, Camparo P, Su X, Yao H, Tamboli P, Lopez-Terrada D, et al. (2013). Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res 19, 4673-4684.
8. Mosquera JM, Dal Cin P, Mertz KD, Perner S, Davis IJ, Fisher DE, Rubin MA, and Hirsch MS (2011). Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas. Diagn Mol Pathol 20, 129-137.
9. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, et al. (2011). The genomic complexity of primary human prostate cancer. Nature 470, 214-220.
10. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, et al. (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113.
11. Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, et al. (2010). Integrative analysis of the melanoma transcriptome. Genome Res 20, 413-427.
12. Maher CA, Palanisamy N, Brenner JC, Cao X, Kalyana-Sundaram S, Luo S, Khrebtukova I, Barrette TR, Grasso C, Yu J, et al. (2009). Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci USA 106, 12353-12358.
13. Pflueger D, Terry S, Sboner A, Habegger L, Esgueva R, Lin PC, Svensson MA, Kitabayashi N, Moss BJ, MacDonald TY, et al. (2011). Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res 21, 56-67.
14. Guo G, Gui Y, Gao S, Tang A, Hu X, Huang Y, Jia W, Li Z, He M, Sun L, et al. (2012). Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 44, 17-19.
15. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, et al. (2011). Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542.
16. Cancer Genome Atlas Research Network (2013). Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43-49.
17. Camparo P, Vasiliu V, Molinie V, Couturier J, Dykema KJ, Petillo D, Furge KA, Comperat EM, Lae M, Bouvier R, et al. (2008). Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol 32, 656-670.
18. Sboner A, Habegger L, Pflueger D, Terry S, Chen DZ, Rozowsky JS, Tewari AK, Kitabayashi N, Moss BJ, Chee MS, et al. (2010). FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biol 11, R104.
19. Bruder E, Moch H, Ehrlich D, Leuschner I, Harms D, Argani P, Briner J, Graf N, Selle B, Rufle A, et al. (2007). Wnt signaling pathway analysis in renal cell carcinoma in young patients. Mod Pathol 20, 1217-1229.
20. Bruder E, Passera O, Harms D, Leuschner I, Ladanyi M, Argani P, Eble JN, Struckmann K, Schraml P, and Moch H (2004). Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol 28, 1117-1132.
21. Mertz KD, Demichelis F, Kim R, Schraml P, Storz M, Diener PA, Moch H, and Rubin MA (2007). Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Hum Pathol 38, 1454-1462.
22. Habegger L, Sboner A, Gianoulis TA, Rozowsky J, Agarwal A, Snyder M, and Gerstein M (2011). RSEQtools: a modular framework to analyze RNA-Seq data using compact, anonymized data summaries. Bioinformatics 27, 281-283.
23. Mortazavi A, Williams BA, McCue K, Schaeffer L, and Wold B (2008). Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5, 621-628.
24. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, et al. (2010). Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363.
25. Kircher M, Stenzel U, and Kelso J (2009). Improved base calling for the Illumina Genome Analyzer using machine learning strategies. Genome Biol 10, R83.
26. Rechsteiner MP, von Teichman A, Nowicka A, Sulser T, Schraml P, and Moch H (2011). VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations. Cancer Res 71, 5500-5511.
27. Bode B, Frigerio S, Behnke S, Senn B, Odermatt B, Zimmermann DR, and Moch H (2006). Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Mod Pathol 19, 541-547.
28. Argani P, Olgac S, Tickoo SK, Goldfischer M, Moch H, Chan DY, Eble JN, Bonsib SM, Jimeno M, Lloreta J, et al. (2007). Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 31, 1149-1160.
29. Martignoni G, Gobbo S, Camparo P, Brunelli M, Munari E, Segala D, Pea M, Bonetti F, Illei PB, Netto GJ, et al. (2011). Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Mod Pathol 24, 1313-1319.
30. Zhong M, De Angelo P, Osborne L, Paniz-Mondolfi AE, Geller M, Yang Y, Linehan WM, Merino MJ, Cordon-Cardo C, and Cai D (2012). Translocation renal cell carcinomas in adults: a single-institution experience. Am J Surg Pathol 36, 654-662.
31. Tanaka M, Kato K, Gomi K, Matsumoto M, Kudo H, Shinkai M, Ohama Y, Kigasawa H, and Tanaka Y (2009). Perivascular epithelioid cell tumor with SFPQ/ PSF-TFE3 gene fusion in a patient with advanced neuroblastoma. Am J Surg Pathol 33, 1416-1420.
32. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, Palanisamy N, and Chinnaiyan AM (2009). Transcriptome sequencing to detect gene fusions in cancer. Nature 458, 97-101.
33. Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, et al. (2009). SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res 69, 2734-2738.
34. Wang X, Yang R, Jadhao SB, Yu D, Hu H, Glynn-Cunningham N, Sztalryd C, Silver KD, and Gong DW (2012). Transmembrane emp24 protein transport domain 6 is selectively expressed in pancreatic islets and implicated in insulin secretion and diabetes. Pancreas 41, 10-14.
35. Smith RD and Lupashin VV (2008). Role of the conserved oligomeric Golgi (COG) complex in protein glycosylation. Carbohydr Res 343, 2024-2031.
36. Tomlinson VA, Newbery HJ, Wray NR, Jackson J, Larionov A, Miller WR, Dixon JM, and Abbott CM (2005). Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer 5, 113.
37. Tomlinson VA, Newbery HJ, Bergmann JH, Boyd J, Scott D, Wray NR, Sellar GC, Gabra H, Graham A, Williams AR, et al. (2007). Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus. Br J Cancer 96, 1613-1620.
38. Scaggiante B, Dapas B, Bonin S, Grassi M, Zennaro C, Farra R, Cristiano L, Siracusano S, Zanconati F, Giansante C, et al. (2012). Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the potential of EEF1A2 as a hallmark for prostate transformation and progression. Br J Cancer 106, 166-173.
39. Shimoda Y and Watanabe K (2009). Contactins: emerging key roles in the development and function of the nervous system. Cell Adh Migr 3, 64-70.
40. Argani P, Antonescu CR, Illei PB, Lui MY, Timmons CF, Newbury R, Reuter VE, Garvin AJ, Perez-Atayde AR, Fletcher JA, et al. (2001). Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 159, 179-192.
41. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, and Ladanyi M (2003). Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol 27, 750-761.
42. Green WM, Yonescu R, Morsberger L, Morris K, Netto GJ, Epstein JI, Illei PB, Allaf M, Ladanyi M, Griffin CA, et al. (2013). Utilization of a TFE3 breakapart FISH assay in a renal tumor consultation service. Am J Surg Pathol 37, 1150-1163.
43. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, et al. (1997). Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16, 68-73.
44. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, et al. (2013). Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 31, 181-186.
45. Minner S, Rump D, Tennstedt P, Simon R, Burandt E, Terracciano L, Moch H, Wilczak W, Bokemeyer C, Fisch M, et al. (2012). Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer 118, 1268-1275.